Articles from Aegis Sciences Corporation

Aegis Sciences Corporation, a health care testing lab based in Nashville, TN, is pleased to announce the second bi-annual update to its novel psychoactive substance (NPS) testing menu.

Aegis Sciences Corporation, a leading national healthcare and forensic toxicology laboratory, today announced the successful completion of a $170 million debt refinancing, advised by CoveView Advisors. Aegis is a portfolio company of Abry Partners, a leading sector-focused North American private equity firm. In addition to contributions from new debt investors led by Kayne Anderson, Abry Partners is providing incremental growth equity capital to support Aegis’s ambitious expansion plans. As part of the transaction, Aegis also retains an undrawn revolving credit facility which will be used to finance future growth investments.

Aegis Sciences Corporation, a health care testing lab based in Nashville, TN, is pleased to announce this year’s first bi-annual update to its novel psychoactive substance (NPS) testing menu.

Aegis Sciences Corporation, a leading provider of innovative toxicology and healthcare testing solutions, proudly announces the launch of MedProtectCDM, a groundbreaking tool designed to enhance clinical decision-making by identifying medication nonadherence and potential drug-drug interactions. This revolutionary oral fluid-based testing solution empowers healthcare providers to optimize treatment strategies for patients receiving treatment for chronic conditions such as hypertension, diabetes, and chronic obstructive pulmonary disease (COPD).

Aegis Sciences Corporation, a leader in toxicology and healthcare services, is excited to announce the launch of a groundbreaking data visualization dashboard designed to provide real-time insights into the presence of novel psychoactive substances (NPS) across the United States. This new interactive tool empowers clinicians, public health officials, policymakers, and the public with critical data to address the evolving landscape of synthetic and designer drugs.

In April 2023, the White House designated the combination of fentanyl and xylazine as an emerging threat to the United States. Despite federal attention, xylazine, a drug not approved for human use that can increase certain effects and risks associated with opioid use, continues to permeate the drug supply throughout the US. Though testing for this substance to assist in treatment decisions has become more common, literature published on the effects of xylazine on withdrawal symptoms remains very limited.

Aegis Sciences Corporation, a health care testing lab based in Nashville, TN, is pleased to announce the second bi-annual update to its novel psychoactive substance (NPS) testing menu.

Nearly 107,000 Americans died from a drug overdose in 2021, according to the Centers for Disease Control and Prevention. More than 80,000 of those deaths (75 percent) were opioid-related and, of those, nearly 71,000 (88 percent) involved high-potency synthetic opioids.1 Synthetic opioids are driving the opioid overdose epidemic: the number of synthetic opioid-related deaths was nearly 23 times higher in 2021 than in 2013, in large part due to use of illicitly-manufactured fentanyl and other emerging synthetic opioid analogs.2

Aegis Sciences Corporation, a leading healthcare company that provides clinically innovative medication compliance testing and consulting services to providers, today announced that several of its applications* have once again achieved HITRUST (r2) Certification for information security.

Please replace the release with the following corrected version due to multiple revisions.

Aegis Sciences Corporation, a health care testing lab based in Nashville, TN, is pleased to announce another expansion of novel psychoactive substance (NPS) testing for its clients. The NPS test menu includes expanded offerings for designer opioids, designer benzodiazepines, synthetic cannabinoids, synthetic stimulants, hallucinogens/dissociatives, and other substances of concern. This update is a revision of both the current oral fluid and urine NPS test menu, to include the removal of analytes which have significantly decreased in prevalence, as well as the addition of new analytes which have entered circulation in the United States.

Aegis Sciences Corporation, a health care testing lab based in Nashville, has published a Journal of Addiction Medicine study finding a widespread presence of the animal tranquilizer xylazine across the U.S. Previously, the use of xylazine has been thought to be primarily a problem in the Northeast region of the country.

Aegis Sciences Corporation, a health care testing laboratory based in Nashville, Tenn., today announced its acquisition of the HealthTrackRx Toxicology line of business.

A manuscript detailing an extensive analysis completed by Aegis Sciences Corporation and Walgreens was published in PLOS ONE yesterday. The manuscript, Validation of reduced S-gene target performance and failure for rapid surveillance of SARS-CoV-2 variants, highlights a unique methodology developed through work by both organizations to create a more comprehensive early warning system during periods of emerging new viral variants.

Aegis Sciences Corporation is launching a key opinion leadership series titled “InPractice: Clinical Insights,” on July 26. The panel will feature health care experts from across the country. This series will consist of timely panel discussions regarding topics affecting the health care industry and the myriad ways in which testing can offer clarity on these issues, including the evolution of the designer drug market, addiction recovery plans, effective utilization of medication monitoring, and more.

Aegis Sciences Corporation, a health care testing lab based in Nashville, Tenn., today announced it is now authorized to begin testing for monkeypox using the U.S. Centers for Disease Control and Prevention (CDC)’s PCR-based Orthopoxvirus DNA assay.

Aegis Sciences Corporation has expanded its molecular testing capabilities to rapidly identify pathogens in the respiratory and urogenital health spaces. With Aegis Infectious Disease Testing, providers will have access to:

Today, Aegis Sciences Corporation launched TestingWorks! to help keep schools open during the COVID-19 pandemic through pooled testing. This testing program was designed to be simple for schools to use while reducing costs and increasing access to testing.